The treatment of diabetic foot infections: Focus on ertapenem

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 949-963

  Edmonds, Michael ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Diabetes; Ertapenem; Foot; Infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDATE SODIUM; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; TIMENTIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BONE BIOPSY; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; DEBRIDEMENT; DIABETIC FOOT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRESS SYNDROME; DRUG COST; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENTEROBACTERIACEAE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; GAS GANGRENE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPERBARIC OXYGEN; LIVER DYSFUNCTION; MALAISE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEPHROTOXICITY; OSTEOMYELITIS; OTOTOXICITY; PROGNOSIS; PSEUDOMONAS; REVASCULARIZATION; REVIEW; SEIZURE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP G; STREPTOCOCCUS INFECTION; TREATMENT DURATION; VOMITING;

EID: 74049116231     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s3162     Document Type: Review

References (51)

1. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990;13:513-521.
2. Bakker K, Foster AVM, van Houtoum WH, et al, eds. International Diabetes Federation and International Working Group of the Diabetic Foot. 2005 Time to Act. The Netherlands.
3. Reiber GE. Epidemiology of foot ulcers and amputations in the diabetic foot. In: Bowker JH, Pfeifer MA Eds. Levin and O'Neal's The Diabetic Foot. 6th Ed. Mosby, St. Louis; 2001:13-32.
4. Lipsky, BA Berendt AR, Gunner Deery H, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885-910.
5. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev. 2004;20 Suppl 1:S68-S77.
6. Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008;24 Suppl 1:S145-S161.
7. Berendt AR, Peters EJ, Bakker K, et al. Specific guidelines for treatment of diabetic foot osteomyelitis. Diabetes Metab Res Rev. 2008;24 Suppl 1:S190-S191.
8. Lipsky BA. New developments in diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev. 2008;24 Suppl 1:S66-S71.
9. Lavery LA, Armstrong DG, Murdoch DP, et al. Validation of the infectious diseases society of America's diabetic foot infection classification system. Clin Infect Dis. 2007;44:562-565.
10. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg. 2006;45:S2-S66.
11. Edmonds M, Foster A, Sanders L. Practical Manual of Diabetic Foot Care. 2nd ed. Oxford: Blackwell; 2008.
12. Citron DM, Goldstein EJ, Merriam CV, et al. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45:2819-2828.
13. Dang CN, Prasad YDM, Boulton AJM, et al. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003;20(2)159-163.
14. Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect. 2006;12:186-189.
15. Ferry T, Etienne J. Community acquired MRSA in Europe. BMJ. 2007;335:947-948.
16. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis. 2008;27:3-15.
17. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid vs ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38:17-24.
18. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. Antimicrob Chemother. 2007;60:819-823.
19. Lipsky BA, Stoutenburgh U, Lipsky BA, et al. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240-245.
20. Legout M, Assal P, Rohner P, et al. Severe Streptococcus agalactiae infection of the diabetic foot. A deleterious role of Streptococcus agalactiae. Presse Med. 2005;34:491-494.
21. Nelson EA, O'Meara S, Golder, et al. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med. 2006;23:348-359.
22. Nelson EA, O'Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess. 2006;10:iii-iv, ix-x, 1-221.
23. Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? Clin Microbiol Infect. 2007;13:351-353.
24. Bader MS. Diabetic foot infection. Am Fam Physician. 2008;78:71-79.
25. Clay PG, Graham MR, Lindsey CC, et al. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. Am J Geriatr Pharmacother. 2004;2:181-189.
26. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem vs piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366:1695-1703.
27. Weigelt J, Itani K, Stevens D, et al; Linezolid CSSTI Study Group Linezolid vs vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260-2266.
28. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2006;12 Suppl 1:24-32.
29. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13:1159-1169.
30. Davis SL, McKinnon PS, Hall LM, et al. Daptomycin vs vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2003;27(12):1611-1618.
31. Sotto A, Bouziges N, Jourdan N, et al. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris). 2007;55:398-406.
32. Lipsky BA, Giordano P, Choudhri S, et al. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007;60:370-376.
33. Raymakers JT, Houben AJ, van der Heyden JJ, et al. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med. 2001;18:229-234.
34. Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt). 2005;6:27-40.
35. Tice AD, Turpin RS, Hoey CT, et al. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm. 2007;64:1080-1086.
36. Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, et al. Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother. 2007;60:893-896.
37. Laethem T, De Lepeleire I, McCrea J, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother. 2003;47:1439-1442.
38. Burkhardt O, Brunner M, Schmidt S, et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother. 2006;58:632-636.
39. Vauthey L, Uçkay I, Abrassart S, et al. Vancomycin-induced DRESS syndrome in a female patient. Pharmacology. 2008;82:138-141.
40. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev. 2009;Issue 3. Art. No. CD006810.
41. Hunt D. Foot ulcers and amputations in diabetes. BMJ Clinical Evidence. 2006. URL http://www.clinicalevidence.com/ceweb/conditions/dia/ 0602/0602-I4.jsp.
42. Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. PMR. 2009;1:471-489.
43. Lipsky BA, Sheehan P, Armstrong DG, et al. Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial. Int Wound J. 2007;4:30-38.
44. Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. Int Wound J. 2004;1:123-132.
45. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated non-surgically: a retrospective cohort study. Diabetes Care. 2006;(4):637-642.
46. Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabetes Metab. 2008;34:87-95.
47. Vekatesan P, Lawn S, Macfarlane RM, et al. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med. 1997;14:487-490.
48. Embil JM, Rose G, Trepman E, et al. Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int. 2006;27:771-779.
49. Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia. 2008;51:962-967.
50. Kapur NK, Musunuru K. Clinical efficiency and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4(2):341-353.
51. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 2002:93-113.